Stocks & Investing
Thu, August 1, 2024
[ 12:00 AM ] - WOPRAI
Wed, July 31, 2024
[ 12:00 AM ] - WOPRAI
Wed, July 17, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, July 9, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, May 13, 2024
[ 12:00 AM ] - WOPRAI
Wed, May 1, 2024
[ 12:00 AM ] - WOPRAI
Mon, April 15, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, April 10, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, January 18, 2024
[ 12:00 AM ] - WOPRAI
Wed, January 17, 2024
[ 12:00 AM ] - WOPRAI
Thu, December 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 1, 2023
[ 12:00 AM ] - WOPRAI
Wed, October 25, 2023
[ 12:00 AM ] - WOPRAI
Mon, October 23, 2023
[ 12:00 AM ] - WOPRAI
Fri, October 20, 2023
[ 12:00 AM ] - WOPRAI
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
Mon, July 24, 2023
[ 12:00 AM ] - WOPRAI
Fri, July 21, 2023
[ 12:00 AM ] - WOPRAI
Thu, July 13, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, May 24, 2023
[ 12:00 AM ] - WOPRAI
Mon, May 15, 2023
[ 12:00 AM ] - WOPRAI
Wed, April 19, 2023
[ 12:00 AM ] - WOPRAI
Matthew Sykes Maintained (CDNA) at Strong Buy with Increased Target to $26 on, Aug 1st, 2024
Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Increased Target from $16 to $26 on, Aug 1st, 2024.
Matthew has made no other calls on CDNA in the last 4 months.
There are 3 other peers that have a rating on CDNA. Out of the 3 peers that are also analyzing CDNA, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Cooper of "Raymond James" Downgraded from Buy to Hold on, Monday, May 13th, 2024
These are the ratings of the 2 analyists that currently disagree with Matthew
- Mason Carrico of "Stephens & Co." Maintained at Buy with Increased Target to $18 on, Monday, May 13th, 2024
- Alexander Nowak of "Craig-Hallum" Upgraded from Hold to Strong Buy and Increased Target to $15 on, Wednesday, May 1st, 2024
